Evidence map›Paper›PMID 40947885›Full record

ArticleBiomacromolecules2025

Polymer Nanomedicines with pH-Triggered Pirarubicin Release: Revealing the Role of Carrier Hydrophilicity and Release Kinetics in Anticancer Performance.

Sára Pytlíková, Benchun Jiang, Lucie Woldřichová, Kevin Kotalík, Ladislav Androvič, Shanghui Gao, Vladimír Šubr, Anna Rumlerová, Robert Pola, Natália Podhorská and 6 more

Abstract read
In one paragraph

Article in Biomacromolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sára PytlíkováInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.
Benchun JiangFaculty of Pharmaceutical Sciences, Sojo University, Kumamoto 860 0082, Japan.
Lucie WoldřichováInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.
Kevin KotalíkInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.
Ladislav AndrovičInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.
Shanghui GaoFaculty of Pharmaceutical Sciences, Sojo University, Kumamoto 860 0082, Japan.
Vladimír ŠubrInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.
Anna RumlerováInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.
Robert PolaInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.ORCID 0000-0003-0025-2016
Natália PodhorskáInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.
Marcela FilipováInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.ORCID 0000-0003-3503-7973
Mingjie ZhangFaculty of Pharmaceutical Sciences, Sojo University, Kumamoto 860 0082, Japan.
Michal PecharInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.ORCID 0000-0002-4507-1801
Jun FangFaculty of Pharmaceutical Sciences, Sojo University, Kumamoto 860 0082, Japan.ORCID 0000-0001-7362-5878
Richard LagaInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.ORCID 0000-0001-5420-2407
Tomáš EtrychInstitute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovského nám. 2, Prague 6 162 00, Czech Republic.ORCID 0000-0001-5908-5182

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic efficacy of antitumor nanomedicines is influenced by numerous factors, with the most critical being the selection of an appropriate biomaterial and the use of suitable stimulus-responsive linkers. The chosen biomaterial must be biocompatible and capable of binding the drug via a linker that facilitates selective release and activation of the therapeutic effect, specifically within tumor tissue. In this study, we designed, synthesized, and compared the physicochemical and biological properties of various polymer nanomedicines, each bearing pirarubicin conjugated to water-soluble and biocompatible methacrylamide-based copolymers through pH-sensitive hydrazone bonds. Our findings indicate that the hydrophobicity and length of the linker near the hydrazone bond are crucial factors influencing the treatment efficacy of the nanomedicines. Conjugates with aminohexanoyl linkers exhibited superior drug release and enhanced antitumor activity compared with those with shorter linkers. Overall, our study highlights that the rate of drug release, governed by the linker structure, plays a pivotal role in therapeutic efficacy, while the hydrophilicity of the polymer backbone has a lesser impact.

Indexed as

Antineoplastic AgentsDoxorubicinDrug CarriersPolymersCell Line, TumorDrug LiberationHumansHydrogen-Ion ConcentrationHydrophobic and Hydrophilic InteractionsKineticsNanomedicineAntineoplastic AgentsDoxorubicinDrug CarrierspirarubicinPolymers

Identifiers

PMID40947885
PMCPMC12522147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.